Reports related to this article:
Project(s): View 2 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
Released July 15, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Most people have at least one medical device. Some, like a thermometer, are kept in a medicine chest; others, like a cardiac stent, are implanted in a person's chest. These two extremes illustrate the vast range of products that fall under this sector. A sound definition of a medical device is an object used in or on a body to alleviate, cure or diagnose a medical condition.
These are heady times for the industry as an avalanche of new products and technologies make it to market. These include 3-D printers capable of making prosthetic limbs, contact lenses that can determine blood glucose levels, optical scanners that eliminate the need for surgical biopsies and needle-free drug delivery--the list of new products is limited only by inventors' imaginations.
Just to keep up with the burgeoning demand and discovery, the sector has $3 billion in active reported capital and MRO investment. A recent analysis of active reported projects in Industrial Info's Pharmaceutical-Biotech Database revealed 278 projects representing a total investment value (TIV) of $2.9 billion. Those figures translate to an average TIV of just over $10 million.
Click the icon at right for a chart showing medical device project investments by market region.
All of the projects are in various stages of development, ranging from planning to construction, for everything from scheduled maintenance programs to grassroot manufacturing plants. Of the 278 analyzed, 167 have a future kick-off date and account for $778 million TIV.
One of the projects in early planning is Bard Shannon Limited's intent to invest $43 million to renovate and expand its vascular, urology and oncology medical devices plant in Humacao, Puerto Rico. Possibly being broken down into a series of smaller project, the plan includes renovation of 70,000 square feet of existing manufacturing suite and construction of an additional 80,000-square-foot production building. Bard Shannon is a subsidiary of C. R. Bard Incorporated (NYSE:BCR) (Murray Hill, New Jersey).
Click here for the 2016 North American Pharmaceutical & Biotech Industry Outlook-Updated Quarterly.
Another major project is the plan by Illumina Incorporated (NASDAQ:ILMN) (San Diego, California) to invest an additional $75 million in its new genome sequencing campus in Foster City, California. Located on the former of site of Life Technologies, following construction of two new, 185,000-square-foot buildings, the company is considering a third 185,000-square-foot building. When construction is complete, the site will consolidate various existing Illumina locations in Northern California, allowing for expanding research and development of genome sequencing equipment and technologies.
The Illumina campus is being developed as a build-to-suit, and is owned by BioMed Realty Trust Incorporated (NYSE:BMR) (San Diego, California). Other current project team members include architects HOK Incorporated (San Francisco, California) and consultant Urban Planning Partners (Oakland, California).
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
These are heady times for the industry as an avalanche of new products and technologies make it to market. These include 3-D printers capable of making prosthetic limbs, contact lenses that can determine blood glucose levels, optical scanners that eliminate the need for surgical biopsies and needle-free drug delivery--the list of new products is limited only by inventors' imaginations.
Just to keep up with the burgeoning demand and discovery, the sector has $3 billion in active reported capital and MRO investment. A recent analysis of active reported projects in Industrial Info's Pharmaceutical-Biotech Database revealed 278 projects representing a total investment value (TIV) of $2.9 billion. Those figures translate to an average TIV of just over $10 million.
Click the icon at right for a chart showing medical device project investments by market region.All of the projects are in various stages of development, ranging from planning to construction, for everything from scheduled maintenance programs to grassroot manufacturing plants. Of the 278 analyzed, 167 have a future kick-off date and account for $778 million TIV.
One of the projects in early planning is Bard Shannon Limited's intent to invest $43 million to renovate and expand its vascular, urology and oncology medical devices plant in Humacao, Puerto Rico. Possibly being broken down into a series of smaller project, the plan includes renovation of 70,000 square feet of existing manufacturing suite and construction of an additional 80,000-square-foot production building. Bard Shannon is a subsidiary of C. R. Bard Incorporated (NYSE:BCR) (Murray Hill, New Jersey).
Click here for the 2016 North American Pharmaceutical & Biotech Industry Outlook-Updated Quarterly.
Another major project is the plan by Illumina Incorporated (NASDAQ:ILMN) (San Diego, California) to invest an additional $75 million in its new genome sequencing campus in Foster City, California. Located on the former of site of Life Technologies, following construction of two new, 185,000-square-foot buildings, the company is considering a third 185,000-square-foot building. When construction is complete, the site will consolidate various existing Illumina locations in Northern California, allowing for expanding research and development of genome sequencing equipment and technologies.
The Illumina campus is being developed as a build-to-suit, and is owned by BioMed Realty Trust Incorporated (NYSE:BMR) (San Diego, California). Other current project team members include architects HOK Incorporated (San Francisco, California) and consultant Urban Planning Partners (Oakland, California).
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
